Jerusalem Pharmaceuticals Co. Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 10.581 million compared to USD 8.253 million a year ago. Operating income was USD 509,303 compared to USD 12,247 a year ago. Net income was USD 361,339 compared to net loss of USD 96,789 a year ago. Basic earnings per share from continuing operations was USD 0.02 compared to basic loss per share from continuing operations of USD 0.005 a year ago. For the half year, sales was USD 19.837 million compared to USD 16.616 million a year ago. Operating income was USD 1.347 million compared to USD 1.263 million a year ago. Net income was USD 1.223 million compared to USD 1.131 million a year ago. Basic earnings per share from continuing operations was USD 0.068 compared to USD 0.063 a year ago.